Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a ...

Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statem ...

Core Insights - Recursion has reached a pivotal moment, transitioning from demonstrating AI's role in drug discovery to showcasing an AI-native operating system that can generate clinical proof and sustainable value [3] - The company enters 2026 with five clinical programs advancing and over $500 million in milestone payments earned to date, reflecting a robust pipeline and disciplined execution strategy [3][6] Business Highlights - Recursion's pipeline is diversified, powered by its AI-native Recursion OS, with both wholly-owned and partnered programs [4] - The company achieved its first clinical validation of the Recursion OS in Familial Adenomatous Polyposis (FAP), with 75% of evaluable patients showing reductions in total polyp burden [6][9] - Recursion has received $134 million in milestone payments from its collaboration with Sanofi, with five discovery program packages accepted to date [6][14] Financial Performance - Total revenue for Q4 2025 was $35.5 million, a significant increase from $4.5 million in Q4 2024, driven by milestone payments and collaboration agreements [15] - Research and development expenses for Q4 2025 were $95.9 million, slightly lower than $98.3 million in Q4 2024, while total R&D expenses for the year were $475.3 million compared to $314.4 million in 2024 [15][22] - The net loss for Q4 2025 was $108.1 million, an improvement from a net loss of $178.9 million in Q4 2024, with a total net loss of $644.8 million for the year [15][22] Pipeline and Milestones - Recursion's pipeline includes several promising candidates, such as REC-4881 for FAP, REC-617 for advanced solid tumors, and REC-7735 for PI3Kα H1047R mutation [7][9] - Upcoming milestones include FDA engagement for REC-4881 and additional Phase 1/2 clinical data expected in 2026 [9][12] - The company anticipates further advancements in its partnered discovery programs, with potential for additional near-term milestones as programs progress [8][14] Cash Position - As of December 31, 2025, Recursion had cash and cash equivalents of $754 million, providing a runway into early 2028 without additional financing [6][15] - The company achieved a cash operating expense of approximately $399.2 million for 2025, reflecting improved operational efficiency [12][22]

Core Insights - Recursion, a clinical stage TechBio company, will be featured in a Lightning Talk at the NVIDIA GTC AI Conference, focusing on the integration of AI, automation, and robotics in drug discovery and development [1][4] Company Overview - Recursion is a leading TechBio company that decodes biology to improve lives, utilizing a platform called Recursion OS to generate one of the largest proprietary biological and chemical datasets [5] - The company operates sophisticated integrated wet and dry labs for AI drug discovery, generating millions of multi-omic data points weekly to enhance the drug discovery process [3][5] - Recursion's operations are supported by its powerful supercomputer, BioHive-2, which facilitates end-to-end improvements in drug discovery, including biological discoveries, precision drug design, and optimized clinical trials [3][5] Collaboration and Technology - Recursion is collaborating with HighRes Biosolutions to develop self-driving, high-throughput labs using advanced automation and orchestration technologies [2] - The collaboration leverages HighRes technologies such as robotic perception and digital twins of laboratory environments, which are essential for creating self-driving laboratories [2] Industry Impact - The advancements in AI and accelerated computing are pushing the boundaries of drug discovery, with NVIDIA's involvement highlighting the transition from concept to reality in Physical AI [4]

Core Insights - Recursion, a clinical stage TechBio company, will provide business updates and report its fourth quarter and full year 2025 financial results on February 25, 2026, before the market opens [1] - The company will host a live earnings call on the same day at 8:00 am ET, allowing investors and the public to submit questions [2] Company Overview - Recursion is focused on decoding biology to improve lives, utilizing its Recursion OS platform to generate one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, operating at a scale of millions of wet lab experiments weekly [3] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, with additional offices in Montréal, New York, London, and the Oxford area [4]

Core Insights - Recursion, a clinical stage TechBio company, has granted inducement restricted stock unit (RSU) awards covering 820,431 shares to 17 new employees as part of its 2024 Inducement Equity Incentive Plan [1][2] Group 1: Inducement RSU Awards - The RSU awards will vest 25% on the first quarterly vesting date after one year from the vesting commencement date, followed by 1/16th of the shares on each subsequent quarterly vesting date [2] - The awards are contingent upon the continued employment of the recipients through the vesting dates and are governed by the terms of the 2024 Plan and grant agreements [2] Group 2: Company Overview - Recursion is focused on decoding biology to improve lives, utilizing a platform known as Recursion OS, which generates one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [3] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers globally, integrating technology, biology, and chemistry to advance medicine [3] Group 3: Company Location and Presence - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [4] - The company has additional offices in Montréal, New York, London, and the Oxford area [4]

Core Insights - The article discusses the potential of artificial intelligence (AI) in drug development, highlighting Recursion Pharmaceuticals as a leader in this space [1][2]. Company Overview - Recursion Pharmaceuticals utilizes its platform, Recursion OS, which processes 65 petabytes of chemical and biological data to virtually test drugs [2]. - The company is currently advancing eight drugs in its developmental pipeline, with half already in clinical trials involving real patients [5]. Financial Projections - Analysts project Recursion's revenue to increase from an anticipated $62 million last year to $83 million this year, with a target of $163 million by 2028 as R&D milestone payments from partners are expected to rise [6]. - The current market capitalization of Recursion Pharmaceuticals is $2.1 billion, with a current stock price of $3.98 [7]. Industry Context - The AI-powered drug development industry is expected to grow at an average annual rate of 30% from now until 2034, indicating significant market potential for companies like Recursion [9].

Group 1: DraftKings - DraftKings shares lost 8% in value last year and closed 35% below their 2025 peak due to slowing growth and competition from platforms like Kalshi and Polymarket [4] - Concerns about competition disrupting DraftKings' growth are considered overblown, as the brand's recognition and partnerships provide significant marketing advantages [5][6] - DraftKings is diversifying its revenue streams, with casino-style gaming accounting for nearly half of its revenue, which may remind investors of its growth potential [7] Group 2: Recursion Pharmaceuticals - Recursion Pharmaceuticals experienced a 44% pullback last year, but 2026 could be a pivotal year for the company [8] - The company has developed an AI-powered drug discovery platform, Recursion OS, which can analyze 65 petabytes of data to predict drug performance [9]

Group 1 - Recursion Pharmaceuticals, Inc. is positioned as a compelling investment in the AI-driven pharmaceutical sector, particularly amidst macroeconomic uncertainties [3][7] - The company operates as a clinical-stage biotechnology firm, focusing on integrating technological innovations to enhance drug discovery [2] - Recursion's proprietary Recursion OS integrates vast biological imaging data into a closed-loop AI experimentation platform, providing a unique capability at petabyte scale [5] Group 2 - Under CEO Chris Gibson, the company has developed the BioHive-2 supercomputer, which is recognized as the industry's most advanced AI platform [6] - Recursion has a substantial cash reserve that is projected to last through 2027, ensuring financial stability and operational capacity for growth [6] - The current trading of RXRX is relatively under the radar, presenting a low-demand entry point with significant upside potential as capital shifts into the AI pharmaceutical sector [7] Group 3 - Unlike competitors such as Eli Lilly and Illumina, which have already seen significant price increases, RXRX offers both strategic positioning and an attractive valuation [4] - The partnership with Nvidia positions Recursion as a core ally in AI-driven drug discovery, enhancing its market appeal [5] - The bullish thesis on Recursion Pharmaceuticals is similar to previous successful analyses of high-growth biotech companies, indicating strong potential for appreciation [8]

Financial Status - Recursion had $755 million in cash at the end of 2025, projecting runway through the end of 2027[18] - The company anticipates a cash burn of less than $390 million in 2026[39] Pipeline and Platform - Recursion has approximately 5 wholly-owned programs in clinical development and around 15 in discovery[17] - The company's platform has generated over $500 million in upfront and milestone payments[17] - Recursion's supercomputer holds ~65PB of data, including 40PB of proprietary data[45] Partnerships - Sanofi has achieved 4 milestones using AI-designed molecules[27] - Roche and Genentech have delivered 6 AI-powered biology maps[27] - Potential Roche and Genentech and Sanofi milestones per small molecule program is >$300M[17] Clinical Program (REC-4881) - In a study, 75% of evaluable patients with FAP responded to REC-4881 with a 43% median reduction in polyp burden at Week 13[68] - At Week 25, 82% of evaluable patients responded to REC-4881, with 73% achieving durable ≥30% reductions and a 53% median polyp burden reduction[71] - Approximately 87% of untreated FAP patients experienced an annual increase in polyp burden, averaging a 60% increase annually[57, 62]